The Technical AnalystExchange: TSX Industry: Drug Manufacturers—Specialty & Generic
HLS THERAPEUTICS INC Price, Forecast, Insider, Ratings, Fundamentals & Signals
2.15% $4.75
America/New_York / 3 mai 2024 @ 14:06
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 151.63 mill |
| EPS: | -1.170 |
| P/E: | -4.06 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 31.92 mill |
| Avg Daily Volume: | 0.0096 mill |
| RATING 2024-05-03 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Strong Buy | |
| P/E: | Sell | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -4.06 | sector: PE 21.44 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -4.13x |
| Company: PE -4.06 | industry: PE 0.983 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-0.0221 (-100.46%) $-4.77 |
| Date: 2024-05-03 |
| Expected Trading Range (DAY) |
|---|
|
$ 4.50 - 5.01 ( +/- 5.37%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $4.75 (2.15% ) |
| Volume | 0.0019 mill |
| Avg. Vol. | 0.0096 mill |
| % of Avg. Vol | 19.77 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For HLS.TO
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
HLS.TO
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular (CV) markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsules; and PERSERIS, an injectable risperidone product for the treatment of schizophrenia. It also offers MyCare psychiatry lab assays and MyCare Insite point of care therapeutic drug-level monitoring tests. In addition, the company holds the U.S. marketing rights of Absorica, a commercial stage dermatology product; Canadian rights of Trinomia for CV therapeutics; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. was founded in 2018 and is headquartered in Etobicoke, Canada.